CyFlow™ CD26 Purified

CyFlow™ CD26 Purified
Target Species: Human
Antigen: CD26
Field of Interest: Immunophenotyping
Clone: BA5b
Regulatory Status: RUO
Alternative Name: ADABP, ADCP2, CD26, DPPIV, TP103
Application: Flow cytometry
Format/Fluorochrome: Purified
Species of Origin: Mouse
Clonality: monoclonal
Isotype: IgG2a
Product number: CG749747

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA VI—WS Code N-L078 Concentration 1 mg/mL Quantity 0.1 mg Volume... more
CyFlow™ CD26 Purified
HLDA WorkshopHLDA VI—WS Code N-L078
Concentration1 mg/mL
Quantity0.1 mg
Volume0.1 mL
ImmunogenA human T cell clone
Background InformationCD26 (DPP-IV; dipeptidyl peptidase IV) is a homodimeric cell surface serine peptidase that degradates IFN-γ-induced cytokines, acts as a T cell costimulatory molecule, and participates in multiple immunopathological roles in leukocyte homing and inflammation. Alterations in its peptidase activity are characteristic of malignant transformation. The enzymatic activity increases dramatically with tumor grade and severity. CD26 is expressed in various blood cell types, but also e.g. in cells that are histogenetically related to activated fibroblasts. Alterations in CD26 density have been reported on circulating monocytes and CD4+ T cells during rheumatoid arthritis and systemic lupus erythematosus.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·> | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·> | Ellingsen T, Hornung N, Møller BK, Hjelm-Poulsen J, Stengaard-Pedersen K: In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand·J·Immunol. 2007·Oct; 66(4):451‑7. <·PMID:·17850590·> | Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, Vanickova Z, Lisa V, Yea C, Sedo A: Expression and enzymatic activity of dipeptidyl peptidase‑IV in human astrocytic tumours are associated with tumour grade. Int·J·Oncol. 2007·Oct; 31(4):785‑92. <·PMID:·17786309·> | Kotacková L, Baláziová E, Sedo A: Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer. Folia·Biol·(Praha). 2009; 55(3):77‑84. <·PMID:·19545486·> | Wong PT, Wong CK, Tam LS, Li EK, Chen DP, Lam CW: Decreased expression of T lymphocyte co‑stimulatory molecule CD26 on invariat natural killer T cells in systemic lupus erythematosus. Immunol·Invest. 2009; 38(5):350‑64. <·PMID:·19811413·> | Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E, Kokubun S: Histogenesis‑specific expression of fibroblast activation proteinand dipeptidylpeptidase‑IV in human bone and soft tissue tumours. Histopathology. 2009·Oct; 55(4):432‑40. <·PMID:·19817894·>

Article successfully added.